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Abstract
Aim: To evaluate the efficacy of a high dose (4g/day) of omega-3-PUFA on the heart rate variability (HRV) characteristics 
in patients with acute myocardial infarction (AMI) and Type 2 Diabetes Mellitus (T2DM)
Material and Methods: The study included 93 patients with AMI and concomitant T2DM during the first 48 hours from the 
onset of the disease. Group 1 comprised 40 patients, who received the standard therapy for AMI. Group 2 consisted of 53 patients, 
who, in addition to the standard treatment, in the absence of contraindications received omega-3-PUFA (4g/day) from the first day 
of therapy.  All patients underwent Holter ECG monitoring on the first and seventh days of hospitalization.
Results: In the first 48 hours of AMI, a strong trend in reduction of SDNN value in the daytime and at night was marked in 
patients of both groups.  There were no significant changes in HRV time-domain indicators during standard therapy in Group 1. 
In contrast, Group 2 was characterized by statistically significant increases in mRR and SDNN values in the daytime, as well as 
RMSSD and pNN50%. This trend was also observed at night.  In Group 2, Mo and HRV TI (in daytime and at night) also changed 
significantly compared to baseline. 
Conclusion: In the patients with AMI and concomitant T2DM, there were significant changes in the main parameters of HRV 
that reflected the decrease in the activity of the parasympathetic nervous system and an increase in the activity of the sympathetic 
nervous system. Use of omega-3-PUFA in addition to standard therapy from the first hours of AMI allowed stabilization of the 
parasympathetic-sympathetic imbalance.
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Introduction
Current research has shown that the low parameters 
of  the  heart  rate  variability  (HRV)  are  correlated  with  the 
risk of sudden death, even more than the parameters of the 
left ventricle ejection fraction or the quality of the ventricle 
arrhythmias during Holter ECG monitoring and physical 
tolerability [1]. The problem of correcting the reduced HRV 
remains to be solved [2].  However, the use of beta-blockers, 
angiotensin-converting  enzyme  inhibitors,  and  calcium 
antagonists may lead to the reduction of the cardiovascular 
death risk and increasing HRV parameters. On the other hand, 
the use of antiarrhythmic agents of classes I and III also leads 
to HRV reduction; nevertheless, applying of these drugs 
to correct reduced HRV in the acute period of myocardial 
infarction has an insufficient evidence base [3-6].
Consequently, the use of omega-3-polyunsaturated 
fatty acids (omega-3-PUFA) is the new strategy direction in 
research; accordingly, the aim of this study was to evaluate the 
efficacy of a high dose (4 g/d) of omega-3-PUFA on the HRV 
characteristics in patients with acute myocardial infarction 
(AMI) and Type 2 Diabetes Mellitus (T2DM).
Material and Methods
The  study  included  93  patients  (73  males  and  20 
females) admitted to the hospital with AMI and concomitant 
T2DM during the first 48 hours from the onset of the disease. 
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The study was approved by the Republican Specialized Center 
of Cardiology Ethics Committee. Written informed consent 
was obtained from each patient.
The patients were divided into two groups. The control 
group  (Group  1)  comprised  40  patients,  who  received  the 
standard therapy for AMI, which included dual antiplatelet 
therapy  (aspirin+clopidogrel),  unfractionated  heparin 
intravenously, beta-blockers (bisoprolol), statins (atorvastatin). 
The study group (Group 2) consisted of 53 patients, who, 
in addition to the standard treatment, in the absence of 
contraindications received omega-3-PUFA (Omacor, Abbot, 
USA) 4 grams per day from the first day of therapy. There 
were no percutaneous coronary interventions in either group. 
Exclusion criteria included severe respiratory and renal-
hepatic failure, malignancy, acute inflammatory diseases, the 
lack of a stable sinus rhythm (atrium fibrillation, paroxysmal 
supraventricular  tachiarrythmias).  In  order  to  evaluate  the 
state of the vegetative nervous system and HRV parameters, 
all patients underwent Holter ECG monitoring on the first 
and  seventh  days  of  hospitalization.  Data  processing  and 
evaluation were performed by the CardioSens+v3.0 program 
(HAI-Medica, Ukraine).
The state of the vegetative status of the patients was 
assessed by the following parameters:
• HRV time-domain indicators: SDNN, RMSSD, pNN50
• HRV frequency-domain indicators: LF, HF, LF/HF, TP
• HRV geometric indicators: IC, Mo, AMo, HRVTI.
These parameters were evaluated both in daytime and 
at night [1]. 
Results were statistically processed using the software 
package Biostat v4.03. Analysis of the distribution of values 
obtained was performed using the Kolmogorov-Smirnov test. 
For data with normal distribution, inter-group comparisons 
were  performed  using  Student’s  t-test.  95%  Confidence 
Interval (95% CI) for quantitative parameters also was applied. 
The Odds Ratio (OR) and 95%CI were calculated with use of 
logistic regression. Taking into account that the distribution 
of the spectral parameters of HRV were expressed in absolute 
units independently on the order of normal distribution, the 
logarithm transformation of the spectral values (LN) was used 
to perform the analysis. For all types of analysis, the value of 
P<0.05 was considered statistically significant.
Results
Both groups of patients were comparable according to 
their major clinical-demographic characteristics (Table 1). The 
average age of patients of Group 1 was 56.6±1.75 (median: 56 
years) and 56.3±1.0 (median: 57 years) for patients of Group 
2.  Among the patients in Group 2, there were more males 
(88.7%) than females (65%) (95% CI: 1.45-12.3; P=0.01). 
There were no statistically significant differences in AMI in 
the incidence rate in relation to the place of localization and 
the presence of Q wave between groups. The average starting 
doses of drugs, which could affect the characteristics of HRV, 
were the same for both groups.
In the first 48 hours of AMI, according to our results, 
a strong trend in reduction of SDNN value in the daytime 
(41.5±1.15 ms  in Group 1 and 38.4±1.42 ms in Group 2) and 
at night (41.1±1.89 ms in Group 1 and  41.9±1.80 ms  in Group 
2) was marked in patients of both groups, which reflected an 
unfavorable prognosis [2].
Dynamics of the HRV time-domain indicators 
during the therapy
In Group 1, there were no significant changes in HRV 
time-domain  indicators  during  standard  therapy  (Table  2). 
The observed tendency to increased RMSSD parameters in 
daytime, and RMSSD and pNN50 at night, had no statistical 
significance;  values  of  pNN50  indicators  in  daytime  even 
diminished on the seventh day of therapy. In contrast, Group 
2, which received high doses of omega-3-PUFA in addition 
to  the  standard  therapy  was  characterized  by  statistically 
significant increases in mRR (P=0.002) and SDNN (P=0.002) 
values  in  the  daytime,  as  well  as  RMSSD  (P=0.004)  and 
pNN50%  (P=0.002),  indicating  increased  activity  of  the 
parasympathetic nervous system. This trend was also observed 
at night, only with a difference concerning pNN50% (P=0.28), 
which was increased on the seventh day of therapy; however, 
these  changes  had  a  statistically  significant  character.  In 
patients receiving omega-3-PUFA, the increase in RMSSD 
(P=0.04) appeared to be higher in statistical significance than 
in the control group.  
Dynamics of HRV frequency-domain indicators 
during therapy
In Group 1, the spectral indicators analysis revealed a 
lack of the significant changes in TP, ULF, LF and HF values 
in daytime and at night during therapy. However, there was not 
a marked reduction of LF/HF indexes in daytime that showed 
reduction in activity of the sympathetic nervous system (Table 
3).
In Group 2, no statistically significant changes in TP, 
ULF, VLF and LF values during daytime and night hours were 
found. Reduction of the LF/HF ratio was observed during both 
day and night; however, this reduction did not reach statistical 
significance.
Table 1. 
Clinical-demographic characteristics of the patients
Indicators Group 1
n = 40
Group 2
n = 53
OR 95% CI P
n % n %
Age, years 56.6±1.75 56.3±1.0 0.88
Мe (95%CI) 56.0 (53.2–60.0) 57.0(53.2-59.4)
Males 26 65.0 47 88.7 4.22 1.45-12.3 0.01
Q-wave 
anterior AMI 9 22.5 16 30.2 1.42 0.58-3.84 0.55
Non-Q-wave 
anterior AMI 20 50.0 19 35.8 0.56 0.24-1.29 0.25
Q-wave 
inferior AMI 6 15.0 13 24.5 1.84 0.63-5.37 0.39
Non-Q-wave 
inferior AMI 5 12.5 3 5.7 0.42 0.09-1.87 0.43
History of 
AMI 10 25.0 9 17.0 0.61 0.22-1.69 0.49
LV EF, % 57.0±1.66 52.6±1.30 52.25-57.51 0.22140                                       A. G. Nikishin et al / International Journal of BioMedicine 4(3) (2014) 138-142
Dynamics of HRV geometry indicators on 
background of therapy 
In Group 1, the the analysis of HRV geometry indicators 
revealed a non-significant increase in IC (by 15.9%), HRV TI 
(by 11.4%), and Mo (by 3.5%) values in daytime, as well as 
reduction of AMo by 11.4% in comparison with initial values 
(Fig.1). In contrast, the value of IC was reduced by 15.3% 
at night. A similar trend was noted in Group 2, except for a 
difference in the daytime (by 10.3%; P=0.002) and nightly 
hours (by 14.8%; P=0.000), including Mo and HRV TI (by 
23.6%; P=0.02), namely, there were statistically significant 
changes compared to baseline. 
Table 2. 
Changes in HRV time-domain indicators during the therapy
Indicators
Group 1, n = 40 Group 2, n = 53
P
admission 7th  day P admission 7th  day P
Day
mRR, мs 853.4±20.3 888.8±20.0 0.22 839.9±18.3 921.5±17.2 0.002* 0.22
SDNN, мs 41.5±1.15 41.6±2.42 0.97 38.4±1.42 44.0±1.82 0.02* 0.42
SDNNi, мs 10.0±0.76 9.51±0,73 0.64 9.12±0.57 10.5±0.94 0.21 0.43
RMSSD, мs 23.6±2.35 26.6±2.77 0.41 24.4±1.36 33.8±2.88 0.004* 0.08
pNN50,% 7.28±1.72 6.10±1.55 0.61 4.01±0.81 7.16±1.03 0.002* 0.56
Night
mRR, мs 915.2±22.4 970.0±26.0 0.11 882.2±18.9 1003.9±18.5 0.000* 0.28
SDNN, мs 41.1±1.89 45.9±2.15 0.10 41.9±1.80 50.0±1.93 0.003* 0.16
SDNNi, мs 9.73±0.70 10.3±0.90 0.62 9.92±0.66 11.7±0.99 0.14 0.31
RMSSD, мs 27.7±2.76 30.3±3.14 0.54 30.2±1.27 39.0±2.77 0.005* 0.04*
pNN50,% 3.96±2.44 9.12±2.37 0.13 7.73±1.89 10.9±2.26 0.28 0.59
  
Table 3.
 Changes in HRV frequency-domain indicators during the therapy
Indicators
Group 1, n = 40 Group 2, n = 53
P
admission 7th  day P admission 7th  day P
Day
LN ТР, мs2 7.19±0.16 7.19±0.17 1.0 7.04±0.14 7.24±0.15 0.33 0.83
LN ULF, мs2 5.49±0.16 5.67±0.17 0.44 5.23±0.16 5.41±0.13 0.39 0.22
LN VLF, мs2 6.48±0.16 6.38±0.18 0.68 6.18±0.14 6.35±0.13 0.38 0.89
LN  LF, мs2 5.46±0.20 5.31±0.23 0.62 5.48±0.18 5.65±0.18 0.51 0.24
LN  HF, мs2 4.68±0.22 4.82±0.22 0.65 4.78±0.19 5.03±0.20 0.37 0.49
LF n,% 66.7±2.39 60.8±3.0 0.13 65.2±2.16 63.5±2.15 0.58 0.45
HF n,% 33.3±2.39 39.2±3.0 0.13 34.7±2.15 36.5±2.15 0.56 0.45
LF/HF 2.86±0.20 2.03±0.23 0.008* 2.46±0.21 2.22±0.18 0.39 0.51
Night
LN ТР, мs2 7.20±0.15 7.38±0.18 0.45 7.18±0.15 7.52±0.15 0.11 0.55
LN ULF, мs2 5.30±0.17 5.57±0.18 0.30 5.16±0.14 5.46±0.13 0.12 0.61
LN VLF, мs2 6.43±0.15 6.64±0.18 0.37 6.35±0.14 6.65±0.15 0.15 0.97
LN  LF, мs2 5.51±0.17 5.53±0.26 0.95 5.65±0.17 5.98±0.19 0.20 0.16
LN  HF, мs2 5.00±0.22 5.17±0.23 0.60 5.06±0.19 5.48±0.19 0.12 0.30
LF n,% 60.8±2.74 58.8±3.19 0.64 62.7±2.26 61.5±2.35 0.71 0.49
HF n,% 39.2±2.74 41.2±3.19 0.64 37.3±2.26 38.5±2.35 0.71 0.49
LF/HF 2.26±0.37 1.81±0.22 0.30 2.27±0.22 2.09±0.19 0.54 0.34
  
Fig.1. IC-index of centralization, stage of centralization of the control of HR; Mo-   
-mode, occurred mostly frequent in this dynamic line, value of cardio interval; 
AMo–amplitude of Mo, reflected stabilizing effect of the centralization of HR; 
HRVTI - the integral of spectrum of distribution rate related to the maximum 
distribution density.
  *- p<0,05 (LF – power in the diapason of low frequencies; HF – power in diapason of high frequencies; LF/HF – ratio of low frequency to high frequency 
ingredients of spectrum, ТР – common spectral power)
  * - p<0.05 (mRR – average duration of all RR intervals, SDNN – standard deviation of all NN-intervals, RMSSD – square root from average sum of square   
differences between adjacent NN-intervals, pNN50 - proportion of interval between adjacent NN more than 50 ms.141 A. G. Nikishin et al. / International Journal of BioMedicine 4(3) (2014) 138-142
Discussion
At the early stage of AMI (2-3 days), HRV has important 
prognostic information and facilitates prognosis of later 
mortality [8]. Recent research has proved that the speed of the 
HRV restoration after AMI is correlated to future risk [9]. In the 
first 48 hours of AMI, according to our results, a strong trend 
in reduction of SDNN value in the daytimeand at night, which   
was marked in patients of both groups,  reflects an unfavorable 
prognosis [2]. An effort to influence on HRV in persons who 
had AMI previously is based on multiple observations, which 
revealed a higher mortality of post-infarction patients with a 
significant reduction of HRV (SDNN<50 mc) [10,11]. Current 
data on the efficacy of using beta-blockers on patients with 
T2DM are limited, despite the statistically significant increase 
in the HRV background of beta-blockers. Identified changes 
seemed to be moderate, mainly at the expense of an increase 
in LF value [12,13]. The mechanism of the Omega-3-PUFA 
effect on the HRV has not been sufficiently studied; however, 
its efficiency has been confirmed in some investigations [7,14]. 
We encountered this problem during our study.  Standard 
therapy, including the usage of beta-blocker bisoprolol during 
the first seven days AMI, did not result in any important change 
in the HRV time-domain parameters (SDNN: 41.6±2.42 ms, 
RMSSD: 26.6±2.77 ms in the daytime and SDNN: 45.9±2.15 
ms, RMSSD: 30.3±3.14 ms at night). 
The clinical state of patients required an increase in 
receiving an average dose of bisoprolol from 3.85±0.37 to 
4.34±0.46 mg/day, which also had no significant effect on 
the parameters of geometry or the spectral domain of HRV. 
The statistically significant reduction of the ratio LF/HF in 
the patients receiving the standard therapy could be explained 
by the fact that they received higher doses of bisoprolol in 
comparison to Group 2, which caused a higher level of 
sympathetic blockade. However, these higher doses did not 
affect the parasympathetic section of nervous system. On 
the contrary, the reception of the addition of the high dose 
of omega-3-PUFA (Omacor, 4 g/day) to the standard therapy 
resulted in a significant increase in SDNN (from 38.4±1.42 
ms to 44.0±1.82 ms (P=0.02), RMSSD from 24.4±1,36 ms 
to  33.8±2.88  ms  (P=0.004),  pNN50%  (from  4.01±0.81% 
to 7.16±1.03% (P=0.002) values in the daytime, as well as 
SDNN from 41.9±1.80 ms to 50.0±1.93 ms (P=0.003) and 
RMSSD  from  30.2±1,27  ms  to  39.0±2.77  ms  (P=0.005) 
at night. The dose of receiving bisoprolol was increased 
non-significantly  (from  3.47±0.19  to  3.95±0.32  mg/day). 
According to the literature, an increase in SDNN, RMSSD, 
pNN50 values, as well as Mo and HRVTI, and reduction of 
LF/HF indicates an increased activity of the parasympathetic 
nervous system. These features lead to the normalization of 
the autonomic imbalance [1,3]. The results obtained were also 
confirmed with geometry indicators of HRV in Group 2: an 
increased Mo (from 816.0±20.1 to 900.0±17.3 ms (P=0.002) 
in  daytime  and  HRV  TI  (from  16.1±0.93  to  19.9±1.27 
(P=0.02)  at  night. The  predisposition  to  the  occurrence  of 
life-threatening HRV disorders relates directly to the increase 
of  sympathetic activity or reduced vagus function that 
characterized  an  unfavorable  nearest  prognosis  in  patients 
with AMI [15-19]. The main purpose of our study was to 
assess the efficacy of a high dose of omega-3-PUFA (4g/day) 
in addition to the standard therapy on the HRV parameters in 
patients at early stage of AMI and concomitant T2DM. Our 
study has demonstrated that using Omega-3-PUFA  4 g/day 
had a positive and statistically significant effect on the HRV 
indicators, namely, the parasympathetic part of the vegetative 
nervous system. Additionally, this regimen allowed the 
occurrence of unfavorable complications to be reduced, even 
in the first seven days of the treatment, and had an impact on 
the further life predictions.
Conclusion
1. In the patients with AMI and concomitant T2DM, 
there were significant changes in the main parameters of HRV 
that reflected the decrease in the activity of the parasympathetic 
nervous system (SDNN, RMSSD, pNN50, Mo HRVTI) and 
an increase in the activity of the sympathetic nervous system 
(LF/HF, AMo).
2.  Use  of  omega-3-PUFA  in  addition  to  standard 
therapy  from  the  first  hours  of AMI  allowed  stabilization 
of the parasympathetic-sympathetic imbalance and, as a 
consequence, reduction of the risk of AMI complications.
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